03Sep/13

Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen … – The Providence Journal

Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen
The Providence Journal
The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS–Genzyme/Bayer HealthCare’s Lemtrada, Biogen Idec/AbbVie’s daclizumab and Roche/Genentech’s ocrelizumab–will generally be reserved for 

03Sep/13

Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen … – PR Newswire (press release)

Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen
PR Newswire (press release)
The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS—Genzyme/Bayer HealthCare’s Lemtrada, Biogen Idec/AbbVie’s daclizumab and Roche/Genentech’s ocrelizumab—will generally be reserved for 

and more »